At a glance
- Originator Pfizer
- Class Antineoplastics; Dipeptides
- Mechanism of Action Farnesyltranstransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 13 Aug 1998 No-Development-Reported for Cancer in USA (Unknown route)
- 18 Jul 1996 Preclinical development for Cancer in USA (Unknown route)